Evidence map›Paper›PMID 32048062›Full record

ArticleEJNMMI research2020

Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors.

Tom A Bäck, Karin Jennbacken, Malin Hagberg Thulin, Sture Lindegren, Holger Jensen, Tove Olafsen, Paul J Yazaki, Stig Palm, Per Albertsson, Jan-Erik Damber and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  14. Review
  15. Advances in immunotyping of colorectal cancer.Frontiers in immunology · 2023
    Review
  16. Review
  17. An ImprovedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Tom A BäckDepartment of Radiation Physics, Institute of Clinical Sciences, University of Gothenburg, Gula stråket 2B SE-413 45, Gothenburg, Sweden. tom.back@radfys.gu.se.ORCID https://orcid.org/0000-0002-3375-9473
Karin JennbackenDepartment of Urology, Institute of Clinical Sciences, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.
Malin Hagberg ThulinDepartment of Urology, Institute of Clinical Sciences, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.
Sture LindegrenDepartment of Radiation Physics, Institute of Clinical Sciences, University of Gothenburg, Gula stråket 2B SE-413 45, Gothenburg, Sweden.
Holger JensenPET and Cyclotron Unit, KF-3982, Rigshospitalet, Copenhagen, Denmark.
Tove OlafsenDepartment of Molecular Imaging and Therapy, Beckman Research Institute of the City of Hope, Duarte, CA, USA.
Paul J YazakiDepartment of Molecular Imaging and Therapy, Beckman Research Institute of the City of Hope, Duarte, CA, USA.
Stig PalmDepartment of Radiation Physics, Institute of Clinical Sciences, University of Gothenburg, Gula stråket 2B SE-413 45, Gothenburg, Sweden.
Per AlbertssonDepartment of Oncology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
Jan-Erik DamberDepartment of Urology, Institute of Clinical Sciences, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.
Anna M WuDepartment of Molecular Imaging and Therapy, Beckman Research Institute of the City of Hope, Duarte, CA, USA.
Karin WelénDepartment of Urology, Institute of Clinical Sciences, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.
University of Gothenburg · SECity of Hope · USAstraZeneca (Sweden) · SERigshospitalet · DKSahlgrenska University Hospital · SE

Funding

Multifunctional immunoPET tracers for pancreatic and prostate cancerR01CA174294 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E, WU, ANNA M · 2013 to 2020
$3.3M
Cancerfonden -NCI NIH HHS R01 CA174294Percy Falks Stiftelse för Forskning Beträffande Prostata- och Bröstcancer -Stiftelsen Jubileumsklinikens Forskningsfond mot Cancer -Strålsäkerhetsmyndigheten -Västra Götalandsregionen ALFVetenskapsrådet -
6 · The paper itself

Abstract

purposeTargeted alpha therapy (TAT) is a promising treatment for micrometastatic and minimal residual cancer. We evaluated systemic α-radioimmunotherapy (α-RIT) of metastatic castration-resistant prostate cancer (mCRPC) using the α-particle emitter

methodsPC3-PSCA cells were implanted subcutaneously (s.c.) and intratibially (i.t) in nude mice. Efficacy of α-RIT (two fractions-14-day interval) was studied on s.c. macrotumors (0, 1.5 and 1.9 MBq) and on i.t. microtumors (~100-200 μm; 0, 0.8 or 1.5 MBq) by tumor-volume measurements. The injected activities for therapies were estimated from separate biodistribution and myelotoxicity studies.

resultsTumor targeting of

conclusionEvaluating fractionated α-RIT with

Indexed as

Alpha particlesAlpha-radioimmunotherapyAstatine-211Intratibial microtumorsMetastatic prostate cancerProstate stem cell antigenTargeted alpha therapy

Identifiers

PMID32048062
PMCPMC7013029
OpenAlexW3005799109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.